Lugano, Switzerland (ots) - The pharmaceutical group in Ticino, global leader in cancer supportive care, supports the International Conference on mobile technology dedicated to improve the quality of life of people with cancer in collaboration with SDA Bocconi and CERGAS Bocconi. The combination of medicine and mobile technology to improve the quality of life of people ...
Bridgewater, New Jersey (ots) - Helsinn Group, the company focused on building quality cancer care, is pleased to announce today that its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc., has been named as one of the 100 best places to work in New Jersey in a survey and award program conducted by NJBIZ which recognizes and honors the state's top employers who show a ...
Lausanne, Switzerland (ots) - - Click here for Picture 1 (http://www.debiotech.com/news/images/nw181_1.png ) The JewelPUMP2, which will be unveiled for the first time at the ATTD 2014 congress on February 5th in Vienna, is a new product dedicated to the Diabetes Type 2 market, based on Debiotech's innovative ...
Lugano, Switzerland (ots) - NEPA is currently under development for the treatment of chemotherapy-induced nausea and vomiting The Swiss pharmaceutical Helsinn Group announced today that on January 22nd the European Medicines Agency (EMA) determined netupitant-palonosetron fixed dose combination (NEPA) Marketing ...
Lugano, Schweiz (ots) - Swiss Pharma Group Helsinn grants exclusive distribution and licensing rights to Angelini, through its subsidiary company CSC Pharmaceuticals, for the commercialization in Austria, Bulgaria, Czech Republic, Hungary , Poland, Romania, Slovak Republic, Georgia, Russia and the other CIS ...
Takeda Pharmaceuticals International GmbH
Zurich Switzerland (ots) - Takeda Pharmaceuticals International GmbH ("Takeda") announced that the European decentralised procedure (DCP) was positively concluded for dexlansoprazole, a proton pump inhibitor (PPI) with a new dual- delayed release technology for the treatment of reflux disease. The regulatory process ...
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
Lugano, Switzerland (ots) - Helsinn Group grants exclusive distribution and licensing rights to Italfarmaco for the commercialization of its compound currently in development for the treatment of anorexia-cachexia syndrome related to non-small cell lung cancer (NSCLC) Helsinn Group is pleased to announce that ...
Aachen, Germany / Redwood City (California), USA (ots) - Grünenthal Group today announced that the company entered into a commercial partnership with AcelRx Pharmaceuticals, Inc. for ZALVISO, a patient-controlled analgesia device for self- administration of sufentanil nanotablets by patients following surgery. The agreement covers the countries of the European Union, ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - Medical oncologists have a vital role to play in cancer care, particularly as treatments become ever more complex, a new position statement from the European Society for Medical Oncology says (http://www.presseportal.ch/go2/new_position_statement ). Medical oncologists are specialist cancer physicians ...
Lugano, Switzerland/Woodcliff Lake, NJ, USA (ots) - Seeking indication for prevention of chemotherapy-induced nausea and vomiting Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the submission of the New Drug Application (NDA) for the investigational ...
Lugano, Switzerland - Beijing, PRC (ots) - Helsinn Group, the independent, privately-owned, Swiss pharmaceutical company, with a worldwide presence built over 35 years, lands in China. Helsinn's Representative Office was officially inaugurated in Beijing, PRC yesterday. With headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United ...
Yverdon, Switzerland (ots) - BPA Solutions SA (BPA), headquartered at Swiss Technopole Yverdon, Switzerland, today announced it has raised development funds from Debiopharm Investment. BPA is a global leading provider of innovative business software solutions based on Microsoft (MS) SharePoint technologies with 800+ customers and 50+ partners worldwide. Profitable ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - A ground-breaking international survey published today, shows that more than half of the world's population live in countries where regulations aiming to stem drug misuse leave patients without access to opioid medicines for managing cancer pain. The results from the Global Opioid Policy Initiative ...
Lugano, Switzerland (ots) - Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its innovative phase III ghrelin receptor agonist in Germany, France, Benelux, UK and Ireland Swiss-based Helsinn group has granted Chugai ...
Lugano, Switzerland (ots) - The Swiss Helsinn Group announced today the formation of a sales organization in the US subsidiary, Helsinn Therapeutics (US) Inc. A commercial organization of 20 people has been engaged throughout the United States. The new oncology sales representatives will be working via a co-detailing agreement for Aloxi® (palonosetron HCl injection), licensed by the Helsinn Group to Eisai, Inc. The ...
Paris (ots) - - CE marks obtained for MyStar Extra® and MyStar SylkFeel® lancing device, respectively, enabling commercialization in the European Union - Scientific data presented at EASD 2013 demonstrate robustness and accuracy[i],[ii] of estimated A1c algorithm in MyStar Extra® At the annual meeting of the ...
ITM Isotope Technologies Munich SE
Garching (ots) - - In-licensing of superior DOTA-Tyr3-octreotide - Pharmaceutical development for treatment of NETs - Excellent pharmacokinetic properties ITM Isotope Technologies Munich AG (ITM) today announced that it has entered into an exclusive licensing agreement with Progenics Pharmaceuticals Inc. for pharmaceutical development and commercialization of ...
Lugano, Switzerland and Barcelona, Spain (ots) - The Swiss pharmaceutical group Helsinn and the Spanish company, Advancell, Advanced In Vitro Cell Technologies, SA, today announced a partnering agreement for the development and worldwide commercialization of ATH008, a new topical product for the prevention and/or ...
Soho Flordis International (SFI)
Bioggio, Switzerland (ots) - Pharmaton and Soho Flordis International (SFI), an international provider of clinically proven natural medicines, announced today the acquisition of Ginsana SA, a leader and innovator in natural medicine products. The acquisition from Pharmaton, a company of the Boehringer Ingelheim ...
München (ots) - New data from the SEVITENSION study show the fixed-dose combination treatment Sevikar® (olmesartan/amlodipine) to be superior to perindopril in combination with amlodipine in reducing central blood pressure When the traditional arm (brachial) method of measurement is used, blood pressure is usually found to be higher than it is in the large central ...
Zug (ots) - AmVac AG announces today that the EU has approved two grant applications under the seventh framework programme (FP7) for the development of innovative vaccines against flu and leishmaniasis. The projects are joint initiatives of AmVac, other European companies and research institutes with leading expertise in vaccine design and development. Total funding for all participating partners is approximately EUR 6 ...
Lugano, Switzerland & Copenhagen, Denmark (ots) - The decision follows promising findings from a Phase IIa Proof-of-Concept study. Helsinn is planning a Phase IIb study with elsiglutide, and study activities are expected to start in H2 2013. The Swiss pharmaceutical group Helsinn, a leading player in the cancer ...
Schlieren-Zurich, Switzerland (ots) - Prionics, a world leader in farm animal diagnostics, has entered into a strategic partnership with the Belgian company Bio-X Diagnostics to make their innovative diagnostic solutions available to global markets. The collaboration will include distribution, product development and production. Through this partnership, Prionics and Bio-X Diagnostics customers will profit from an ...
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and ...
Lugano/Glattbrugg, Switzerland (ots) - Helsinn Healthcare SA and Vifor Pharma, announced that the companies have entered into an exclusive license and distribution agreement for netupitant-palonosetron fixed dose combination, a Helsinn product currently in the development stage for the treatment of ...
Basel/Milan (ots) - On Saturday April 20, Italian animal rights extremists invaded laboratories at the University of Milan and the associated National Institute of Neurosciences to destroy a large number of important research projects. On behalf of more than 6000 researchers worldwide, the Basel Declaration condemns ...
Lugano, Switzerland/Raleigh, N.C. (ots) - The Swiss pharmaceutical Helsinn Group, a leading player in the cancer supportive care arena, announced today that DARA BioSciences, Inc., a U.S. specialty pharmaceutical company focused on oncology and oncology supportive care products, has launched Gelclair® into the U.S. ...
Lugano, Switzerland (ots) - Helsinn Group has entered into a new partnership with Healthcare Businesswomen's Association (HBA). HBA is the premier catalyst for the leadership development of women, to further the advancement and impact of women in healthcare worldwide. HBA accomplishes this by providing educational opportunities to develop cutting-edge industry ...